Xyloketal B, a marine compound, acts on a network of molecular proteins and regulates the activity and expression of rat cytochrome p450 3a: A bioinformatic and animal study

Junhui Su, Cui Chang, Qi Xiang, Zhi Wei Zhou, Rong Luo, Lun Yang, Zhi Xu He, Hongtu Yang, Jianan Li, Yu Bei, Jinmei Xu, Minjing Zhang, Qihao Zhang, Zhijian Su, Yadong Huang, Jiyan Pang, Shu Feng Zhou

Research output: Contribution to journalArticlepeer-review

Abstract

Natural compounds are becoming popular for the treatment of illnesses and health promotion, but the mechanisms of action and safety profiles are often unknown. Xyloketal B (XKB) is a novel marine compound isolated from the mangrove fungus Xylaria sp., with potent antioxidative, neuroprotective, and cardioprotective effects. However, its molecular targets and effects on drug-metabolizing enzymes are unknown. This study aimed to investigate the potential molecular targets of XKB using bioinformatic approaches and to examine the effect of XKB on the expression and activity of rat cytochrome P450 3a (Cyp3a) subfamily members using midazolam as a model probe. DDI-CPI, a server that can predict drug–drug interactions via the chemical–protein interactome, was employed to predict the targets of XKB, and the Database for Annotation, Visualization and Integrated Discovery (DAVID) was used to analyze the pathways of the predicted targets of XKB. Homology modeling was performed using the Discovery Studio program 3.1. The activity and expression of rat hepatic Cyp3a were examined after the rats were treated with XKB at 7 and 14 mg/kg for 8 consecutive days. Rat plasma concentrations of midazolam and its metabolite 1′-OH-midazolam were determined using a validated high-performance liquid chromatographic method. Bioinformatic analysis showed that there were over 324 functional proteins and 61 related signaling pathways that were potentially regulated by XKB. A molecular docking study showed that XKB bound to the active site of human cytochrome P450 3A4 and rat Cyp3a2 homology model via the formation of hydrogen bonds. The in vivo study showed that oral administration of XKB at 14 mg/kg to rats for 8 days significantly increased the area under the plasma concentration-time curve (AUC) of midazolam, with a concomitant decrease in the plasma clearance and AUC ratio of 1′-OH-midazolam over midazolam. Further, oral administration of 14 mg/kg XKB for 8 days markedly reduced the activity and expression of hepatic Cyp3a in rats. Taken together, the results show that XKB could regulate networks of molecular proteins and related signaling pathways and that XKB downregulated hepatic Cyp3a in rats. XKB might cause drug interactions through modulation of the activity and expression of Cyp3a members. More studies are warranted to confirm the mechanisms of action of XKB and to investigate the underlying mechanism for the regulating effect of XKB on Cyp3a subfamily members.

Original languageEnglish (US)
Pages (from-to)2555-2602
Number of pages48
JournalDrug Design, Development and Therapy
Volume8
DOIs
StatePublished - Dec 12 2014
Externally publishedYes

Keywords

  • Bioinformatics
  • Cytochrome P450 3A
  • DAVID
  • DDI-CPI tool
  • Midazolam
  • Molecular target
  • Pharmacokinetics
  • Rat
  • Xyloketal B

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Xyloketal B, a marine compound, acts on a network of molecular proteins and regulates the activity and expression of rat cytochrome p450 3a: A bioinformatic and animal study'. Together they form a unique fingerprint.

Cite this